Chief Technical Officer · CRISPR Therapeutics AG · CRISPR Therapeutics AG — Stock Option (Right to Buy)
Side
A
Value
—
Shares
90.0K
Price
—
Executed
Nov 4, 2026
Disclosed
Nov 6, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 4 executedNov 6, 2026 disclosed
CRSP · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
CRISPR Therapeutics AG — Stock Option (Right to Buy)
Ticker
CRSP
Shares
90.0K
Price per share
$0
Execution date (reported)
Nov 4, 2026
Owned after transaction
90.0K shares
Days from execution to publication
2
What this establishes
Sakhamuri Sivakesava filed this Form 4 reporting a grant or award of CRSP on Nov 4, 2026. It became public on Nov 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Technical Officer
Sakhamuri Sivakesavacik:0002158086
Issuer
CRISPR Therapeutics AGcik:0001674416
Revision history · 0
No field has changed since this record was first ingested.
